-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Cidofovir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/113852-37-2.gif)
| Category | Cytomegalovirus (CMV) |
| CAS | 113852-37-2 |
| Description | Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively. |
Product Information
| Synonyms | Vistide; HPMPC; (S)-HPMPC; Cidofovir anhydrous; GS-504; GS 504; GS504; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid |
| IUPAC Name | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid |
| Molecular Weight | 279.19 |
| Molecular Formula | C8H14N3O6P |
| Canonical SMILES | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O |
| InChI | InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1 |
| InChIKey | VWFCHDSQECPREK-LURJTMIESA-N |
| Boiling Point | 609.5±65.0°C (Predicted) |
| Melting Point | 260°C (dec.) |
| Flash Point | 322.4±34.3 °C |
| Purity | ≥98% by HPLC |
| Density | 1.76±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in Deionized Water (≥5 mg/mL, Warmed) |
| Appearance | Powder |
| Storage | Store at -20°C |
| Complexity | 417 |
| Exact Mass | 279.06202217 |
| Index Of Refraction | 1.656 |
| In Vitro | The minimum concentrations of (S)-HPMPC required to inhibit CMV plaque formation by 50% was microgram/ml. The selectivity indices of (S)-HPMPC, as determined by the ratio of the 50% inhibitory concentration for cell growth to the 50% inhibitory concentration for plaque formation for CMV (AD-169 strain), was 1,500. The time course of uptake of HPMPC into Vero cells was linear between 10 and 75 min and proportional to the concentration in the medium from 10(-6) to 10(-2) M. |
| In Vivo | Levels of cidofovirin serum following intravenous infusion were dose proportional over the dose range of 1.0 to 10.0 mg/kg of body weight and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2.6 +/- 1.2 h (n = 25). Cidofovir has in vivo anti-CMV activity demonstrated by prolonged clearing of CMV viruria |
| PSA | 157.71000 |
| Target | CMV; DNA/RNA Synthesis; Orthopoxvirus; Apoptosis; Endogenous Metabolite |
| Vapor Pressure | 0.0±4.0 mmHg at 25°C |
| XLogP3-AA | -3.6 |
